Resources

Plan Sponsor News – FTC Report on “PBM Rebate Walls”

“PBMs are incentivized to select higher list price drugs instead of lower list price drugs for their formularies in order to collect a higher rebate…” is one of…

Download Plan Sponsor News PDF

Related Services

Defending Pharmacies in PBM Audits
Payor Network Access and Defense of Network Terminations
Plan Sponsors and Pharmacy Benefit Design and Disputes

Topics

Pharmacy Law
PBM

Life Sciences & Pharmacy

Call Us Now

Plan Sponsor News – FTC Report on “PBM Rebate Walls”

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs

Plan Sponsor News – FTC Report on “PBM Rebate Walls”

Related Insights

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs